{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:13:57Z","timestamp":1772255637747,"version":"3.50.1"},"reference-count":60,"publisher":"Informa UK Limited","issue":"6","funder":[{"name":"Alnylam, Eisai, GlaxoSmithKline, MSD, Merck KGaA, Novartis, Pfizer, and Sanofi"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.4155\/fmc.15.26","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T11:38:43Z","timestamp":1432208323000},"page":"727-735","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Repurposing Pharma Assets: An Accelerated Mechanism for Strengthening the Schistosomiasis Drug Development Pipeline"],"prefix":"10.1080","volume":"7","author":[{"given":"Roopa","family":"Ramamoorthi","sequence":"first","affiliation":[{"name":"BIO Ventures for Global Health, 401 Terry Avenue North, Seattle, WA98109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katy M","family":"Graef","sequence":"additional","affiliation":[{"name":"BIO Ventures for Global Health, 401 Terry Avenue North, Seattle, WA98109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Dent","sequence":"additional","affiliation":[{"name":"BIO Ventures for Global Health, 401 Terry Avenue North, Seattle, WA98109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,5,21]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70794-7"},{"key":"e_1_3_3_4_1","unstructured":"World Health Organization\n          . Schistosomiasis Fact sheet No. 115. www.who.int\/mediacentre"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.1.97"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/095646249400500517"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000210614.45212.0a"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001396"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12087"},{"key":"e_1_3_3_10_1","unstructured":"ClinicalTrials Database: NCT02337855\n          . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02337855"},{"key":"e_1_3_3_11_1","unstructured":"World Health Organization\n          . Preventative Chemotherapy in Human Helminthiasis. Geneva. http:\/\/whqlibdoc.who.int"},{"key":"e_1_3_3_12_1","unstructured":"Merck KGaA\n          . Corporate Social Responsibility Report 2012 \u2013 Philanthropy and product donations. Darmstadt. http:\/\/reports.merckgroup.com"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2013.45.1.32"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2003.12.003"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2005.05.002"},{"key":"e_1_3_3_16_1","unstructured":"TI Pharma\n          . Pediatric Praziquantel Consortium awarded US $1.86 million GHIT grant. www.tipharma.com"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-012-3151-z"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2144"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006732"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis976"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002975"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/651682"},{"key":"e_1_3_3_23_1","unstructured":"World Health Organization\n          . WHO Model List of Essential Medicines \u2013 18th List. Geneva. http:\/\/apps.who.int"},{"key":"e_1_3_3_24_1","unstructured":"ClinicalTrials Database: NCT01054651 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01054651"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70161-4"},{"key":"e_1_3_3_26_1","unstructured":"ClinicalTrials Database: NCT00510159 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00510159"},{"key":"e_1_3_3_27_1","unstructured":"ClinicalTrials Database: NCT01132248 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01132248"},{"key":"e_1_3_3_28_1","unstructured":"ISRCTN registry\n          . Praziquantel praziquantel plus mefloquine and praziquantel plus mefloquine-artesunate in the treatment of schistosomiasis.http:\/\/www.isrctn.com\/ISRCTN00393859"},{"key":"e_1_3_3_29_1","unstructured":"ClinicalTrials Database: NCT01529710 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01529710"},{"key":"e_1_3_3_30_1","unstructured":"ISRCTN registry\n          . Mefloquine and artesunate against schistosomiasis.www.isrctn.com\/ISRCTN06498763"},{"key":"e_1_3_3_31_1","unstructured":"ClinicalTrials Database: NCT01459146 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01459146"},{"key":"e_1_3_3_32_1","unstructured":"World Health Organization\n          . International Clinical Trials Registry Platform (ICTRP) Search Portal. (2014).http:\/\/apps.who.int\/trialsearch\/Default.aspx"},{"issue":"24","key":"e_1_3_3_33_1","first-page":"3531","article-title":"Antimalarials in the treatment of schistosomiasis","volume":"18","author":"Keiser J","year":"2012","unstructured":"Keiser J , UtzingerJ. Antimalarials in the treatment of schistosomiasis. Curr. Pharm. Des.18 (24), 3531\u20133538 (2012).","journal-title":"Curr. Pharm. Des."},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70078-0"},{"key":"e_1_3_3_35_1","first-page":"172","article-title":"The cost of new drug discovery and development","volume":"4","author":"Dickson M","year":"2004","unstructured":"Dickson M , GagnonJP. The cost of new drug discovery and development. Discov. Med.4, 172 (2004).","journal-title":"Discov. Med."},{"key":"e_1_3_3_36_1","unstructured":"Pharmaceutical Research and Manufacturers of America\u00ae (PhRMA)\n          . Clinical trials: the phases of drug testing and approval. www.phrma.org\/innovation"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1179\/136485908X252214"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2006.03.003"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.9.1557"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000350"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-706X(01)00138-3"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr178"},{"key":"e_1_3_3_43_1","unstructured":"Special Program for Research and Training in Tropical Diseases (TDR)\n          . The TDR Targets Database v5. http:\/\/tdrtargets.org"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087594"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/wmts.19"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2014.00317"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2014.09.004"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1112"},{"key":"e_1_3_3_49_1","article-title":"Time course for blood pressure lowering of dihydropyridine calcium channel blockers","volume":"8","author":"Ghamami N","year":"2014","unstructured":"Ghamami N , ChiangSH, DormuthC, WrightJM. Time course for blood pressure lowering of dihydropyridine calcium channel blockers. Cochrane Database Syst. Rev.8, CD010052 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_50_1","first-page":"175","article-title":"HDAC inhibitors and cancer therapy","volume":"67","author":"Atadja PW","year":"2011","unstructured":"Atadja PW . HDAC inhibitors and cancer therapy. Prog. Drug Res.67, 175\u2013195 (2011).","journal-title":"Prog. Drug Res."},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.246"},{"key":"e_1_3_3_52_1","unstructured":"Access to Medicine Index Foundation\n          . Access to Medicine Index 2014. Haarlem. (2014). www.accesstomedicineindex.org"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000478"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003645"},{"key":"e_1_3_3_55_1","unstructured":"Merck Sharp & Dohme Corp. www.merck.com\/index.html"},{"key":"e_1_3_3_56_1","unstructured":"BIO Ventures for Global Health\n          . Current Programs: WIPO Re:Search. (2015). www.bvgh.org\/Current-Programs\/WIPO-ReSearch.aspx"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.4155\/ppa.13.49"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2014.09.002"},{"key":"e_1_3_3_59_1","unstructured":"BIO Ventures for Global Health\n          . WIPO Re:Search partnership stories (2012\u20132013). Seattle. (2014)."},{"key":"e_1_3_3_60_1","unstructured":"World Intellectual Property Organization\n          . WIPO Re:Search (2015). www.wipo.int\/research\/en\/"},{"key":"e_1_3_3_61_1","unstructured":"World Intellectual Property Organization\n          . WIPO Re:Search Guiding Principles. www.wipo.int"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00169467"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc.15.26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:50:09Z","timestamp":1716479409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc.15.26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.4155\/fmc.15.26"],"URL":"https:\/\/doi.org\/10.4155\/fmc.15.26","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725849706.793510455","asserted-by":"object"}]},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}